Quartet Medicine

About:

Quartet Medicine is discovering and developing novel treatments

Website: http://quartetmedicine.com

Twitter/X: quartetmed

Top Investors: Atlas Venture, Pfizer Venture Investments, Novartis Venture Fund, Partners Innovation Fund, ShangPharma Innovation

Description:

Quartet Medicine is a private, biotechnology company focused on discovering and developing novel treatments for chronic pain and inflammation. Human genetics and preclinical target validation data point to increased tetrahydrobiopterin (BH4) as a critical mediator of peripheral nerve dysfunction and immune cell regulation. Quartet is capitalizing on these insights by safely restoring BH4 homeostasis in neuronal and inflammatory cells. Quartet was founded by scientists at Boston Children’s Hospital and École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland in conjunction with Atlas Venture. Quartet’s Series A investors included Atlas Venture, Novartis Venture Funds, Pfizer Venture Investments and Partners Innovation Fund. The company is based in Cambridge, Massachusetts and has research efforts underway with collaborators in Europe and Asia

Total Funding Amount:

$23M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2013-01-01

Contact Email:

info(AT)quartetmedicine.com

Founders:

Kevin Pojasek

Number of Employees:

1-10

Last Funding Date:

2015-10-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai